Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03661346 · ClinicalTrials.gov registry record · Phase 2

Esmolol vs. Labetalol in Endoscopic Sinus Surgery

A Phase 2 study of Chronic Sinusitis, sponsored by The University of Texas Medical Branch, Galveston.

Completed
Registry status
Phase 2
Development phase
28
Enrollment target
1
Study location

NCT03661346 is a Phase 2 study of Chronic Sinusitis that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 28 participants, below the 193-participant average among 9 other Chronic Sinusitis trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03661346, a Phase 2 study of Chronic Sinusitis, has completed, sponsored by The University of Texas Medical Branch, Galveston.

COMPLETED
Registry status
Phase 2
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to compare esmolol and labetalol bleeding and intra-operative visibility scores in functional endoscopic sinus surgery.

Conditions Studied

Interventions

  • DRUG Labetalol
  • DRUG Esmolol

Study Locations (1)

Texas

  • University of Texas Medical Branch - Galveston

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2017-03-01
Est. Completion 2018-03-30
Phase Phase 2

What the Registry Record Tells You About NCT03661346

The ClinicalTrials.gov registry entry for NCT03661346 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 9 other Chronic Sinusitis trials with a reported enrollment target (85% lower). The listed sponsor is The University of Texas Medical Branch, Galveston, which has 203 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Sinusitis appearing as the primary indexed condition, and to 2 interventions - of which Labetalol is the first listed.

NCT03661346 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03661346 about?

NCT03661346 is a clinical study titled "Esmolol vs. Labetalol in Endoscopic Sinus Surgery". The purpose of this study is to compare esmolol and labetalol bleeding and intra-operative visibility scores in functional endoscopic sinus surgery.

What is the current status of trial NCT03661346?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2017-03-01. Estimated completion is 2018-03-30.

What conditions does trial NCT03661346 study?

This clinical trial studies the following conditions: Chronic Sinusitis.

What interventions are being tested in trial NCT03661346?

The interventions under investigation include: Labetalol (DRUG), Esmolol (DRUG).

Who is sponsoring clinical trial NCT03661346?

This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03661346 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Sinusitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.